Maynard Um
-
-
-
-
-
-
-
Incyte (INCY) PT Raised to $123 at Stifel Following 'Solid' Q1 Results
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
-
-
-
-
-
-
-
Incyte names three executives to expanded leadership roles
-
-
-
-
-
-
-
Jefferies on Incyte (INCY): 'Growth Pipeline Remains Focuses'
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Incyte (INCY)
-
-
-
-
-
-
-
Incyte presents data showing 90% response rate for blood cancer drug
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
396,336 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

